Novo Nordisk forms cardiometabolic drug discovery accelerator to get to research faster
Novo Nordisk is now tapping into earlier stages of cardiometabolic research by bringing together academic institutions and German drug discovery shop Evotec after it bought a couple of startups and inked multiple biotech collaborations this summer.
Following a chronic kidney disease tie-up in 2020, the Danish Big Pharma and Evotec are coming together again to form a translational drug discovery accelerator dubbed LAB eN². It’s named after the companies’ initials and is a joint collaboration between Evotec and Novo’s Bio Innovation Hub, an external innovation unit of the pharma based in Cambridge, MA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.